UIA
MRNA icon

Ulland Investment Advisors’s Moderna MRNA Stock Holding History

Ulland Investment Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8
Closed -$1K – 232
2024
Q1 		$1K Buy
+8
New +$806 ﹤0.01% 220

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ulland Investment Advisors's MRNA Position: Q2 2024 in Review

Ulland Investment Advisors sold out of Moderna (MRNA) in Q2 2024, closing a stake of 8 shares — an estimated $1K sold.

Ulland Investment Advisors first reported a position in MRNA in Q1 2024 and held it in 1 quarter. The position peaked at $1K in Q1 2024. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • Ulland Investment Advisors reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • Ulland Investment Advisors sold 8 Moderna shares in Q2 2024, an estimated $1K.
  • Ulland Investment Advisors first reported a position in Moderna in Q1 2024 and held it in 1 quarter.
  • Ulland Investment Advisors's Moderna position peaked at $1K in Q1 2024.
  • 954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Ulland Investment Advisors's 13F filing for Q2 2024, filed 16 Jul 2024.